Barely days after the largest pharmaceutical merger deal of Bristol-Myers/Celgene, valued at $74 billion, another multibillion-dollar buyout of this year has just been announced - Eli Lilly and Co.'s (LLY) acquisition of Loxo Oncology Inc. (LOXO) for $235.00 per share in cash, or roughly $8.0 billion.
Loxo Oncology is a biopharmaceutical company focused on developing highly selective medicines for patients with genomically defined cancers. The acquisition of Loxo is expected to broaden the scope of Lilly's oncology portfolio.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.